Patent · US Active

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

US11408001B1 · kind B1 · utility

0Cited by

9References

29Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Kevin Fitzgerald · Brookline, US
William Querbes · Boston, US
James Butler · Lynnfield, US
Stephanie Williams · Littleton, US
Abigail Liebow · Somerville, US
Gregory Hinkle · Plymouth, US
Martin Maier · Cambridge, US
Stuart Milstein · Cambridge, US
Satyanarayana Kuchimanchi · Cambridge, US
Muthiah Manoharan · Carlsbad, US

Key dates

Filing date	Jun 15, 2021
Grant date	Aug 9, 2022
Priority date	—
Expiry date	Jun 15, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.